Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )
Sidec announced today the first Protein Tomography(TM) Award. The winningproject will obtain a Protein Tomography(TM) collaboration financed by Sidec.This announcement was made at Sidec's Executive Forum during the fourthAnnual PEGS meeting organized by CHI.
Advertisement
The use of Protein Tomography(TM) to answer questions related totherapeutic antibody development was presented at Sidec's Executive Forum.Berkley Lynch, previously Principal Investigator at UCB, spoke about the useof Protein Tomography(TM) to Image the Synaptic Vesicle of protein 2A in situand Jose R. Casas-Finet, Director, R&D and Medical Biochemistry, MedImmuneshowed how antibody conformations and interactions can be studied by ProteinTomography(TM). At the Forum, Wim, K. Bleeker, Director TranslationalResearch & Pharmacology at Genmab presented the modes of action of HuMax-EGFr(zalutumumab) published in PNAS April 22nd and how this was determinedtogether with Sidec using Protein Tomography(TM).
Finally, Kathleen Madden Williams, PhD, JD Edwards Agnell Palmer & DodgeLLP discussed the ever-narrowing tunnel that present day patent protection onantibodies has entered and whether there is a gold standard by whichantibodies are distinguishable from one another thereby to enable moremeaningful patent protection.
"During PEGS it became obvious that studying molecular mechanisms isindeed a crucial step in antibody development. Even for some of the beststudied anti cancer drug targets, such as CD20, a fundamental understandingof the drug mechanisms is still lacking. Hence, Sidec's ProteinTomography(TM) Award fills an important role in encouraging research groupsin the biopharmaceutical industry to try a new avenue, such as ProteinTomography(TM), to increase their chances of success" says Hans Johansson CEOat Sidec AB.
About Sidec:
Sidec studies molecular interactions in situ and in vitro using itsproprietary technology Protein Tomography(TM). Sidec AB offers collaborativeresearch projects to the biopharmaceutical industry that reveal uniqueinformation to prioritize the most promising therapeutic antibody and tolocate the antibody binding epitope.
http://www.sidec.com
SOURCE Sidec AB
